Quviviq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9732075 IDORSIA Benzimidazole-proline derivatives
Jun, 2033

(9 years from now)

US9790208 IDORSIA Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560 IDORSIA Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

Quviviq is owned by Idorsia.

Quviviq contains Daridorexant Hydrochloride.

Quviviq has a total of 3 drug patents out of which 0 drug patents have expired.

Quviviq was authorised for market use on 07 April, 2022.

Quviviq is available in tablet;oral dosage forms.

Quviviq can be used as treatment of insomnia.

Drug patent challenges can be filed against Quviviq from 2026-04-07.

The generics of Quviviq are possible to be released after 02 December, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: 2026-04-07

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia


More Information on Dosage

QUVIVIQ family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic